Biaxin (clarithromycin) based antibiotic therapy in previously untreated, advanced stage indolent lymphoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Clarithromycin (Primary)
- Indications Lymphoma
- Focus Therapeutic Use
- 18 Sep 2014 Biomarkers information updated
- 11 Oct 2013 Planned end date changed from 1 Apr 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
- 10 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.